Sionna cancels PDUFA for drug candidate, cites business review
Sionna Therapeutics has voluntarily withdrawn its New Drug Application for STX001, which had a Prescription Drug User Fee Act date, to conduct a strategic business review. The company anticipates that the application will not be re-filed in its current form.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day